Indogulf Q1 FY27: consolidated PAT down 38% YoY as margins compress to 1.4%

Indogulf Cropsciences reported consolidated Q1 FY27 (quarter ended June 30, 2026) revenue of ₹168.5 Cr, down 11.0% YoY from ₹189.4 Cr, though up 11.8% sequentially from ₹150.8 Cr in Q4 FY26. Consolidated PAT fell to ₹2.41 Cr — down 37.6% YoY from ₹3.87 Cr and down 79.2% QoQ from ₹11.61 Cr — with basic EPS at ₹0.38 versus ₹0.80 a year ago and ₹2.30 in the preceding quarter. Standalone PAT of ₹2.27 Cr fell a comparatively smaller 23.2% YoY (standalone revenue -12.3% YoY to ₹162.4 Cr), so the wider consolidated decline signals a weaker contribution from the two subsidiaries, Abhiprakash Globus Private Limited and Indogulf Cropsciences Australia Pty Ltd, versus a year ago. Net profit margin compressed to 1.43% of total income from 2.03% a year ago and 7.60% in Q4 FY26 — the compression shows up even as revenue grew sequentially, so the pressure is on the cost side rather than volumes. No single expense line stands out as an outlier; the combined weight of raw-material, employee and other operating costs against a YoY-softer topline drove the squeeze. Exceptional items were negligible (~₹3 lakh, both this quarter and a year ago) and were not a factor. No formal analyst consensus or brokerage preview for this print turned up in a web search — Indogulf is a recently listed small-cap without established sell-side coverage, so vsStreet is unknown. The results were approved at the August 12, 2026 board meeting alongside a separate IPO fund-utilization report for the quarter, filed the same day; auditors issued an unmodified limited-review opinion on both statements. No standalone management press release accompanied the filing beyond the board-outcome letter, so there is no additional management commentary to reconcile against the print. The quarter directly confirms management's May 2026 caution that FY27 would see "near-term volatility from weather, inventory corrections, and input costs" ahead of an anticipated stabilization from firming prices and a richer product mix — Q1's YoY revenue decline and sharp margin compression validate that near-term-weak framing (guidance met, in the sense of confirming the warned volatility). The promised price/mix-driven margin recovery is now the marker to verify from Q2 onward.